PLN Gene Cardiomyopathy, Hypertrophic, Type 18 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines

تحليل جين PLN لاعتلال عضلة القلب الضخامي النوع 18 (NGS) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي

Executive Summary | ملخص تنفيذي

ضمان الدقة: حساسية تشخيصية بنسبة 99.9% عبر معالجة معتمدة من ISO. الخدمات اللوجستية المتميزة: جمع منزلي بجودة المستشفيات عبر سلسلة تبريد معتمدة وسحب دم متنقل VIP. التوجيه السريري: استشارة هاتفية بعد الفحص لتفسير النتائج. التأمين: التحقق المباشر من التغطية التأمينية عبر واتساب +971 54 548 8731.

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain and VIP Mobile Phlebotomy.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Overview

The PLN gene test identifies pathogenic variants in phospholamban linked to hypertrophic cardiomyopathy type 18, a hereditary cardiac muscle disorder. This next‑generation sequencing (NGS) assay provides definitive molecular confirmation for UAE patients at familial risk, enabling early clinical intervention and cascade screening.

Feature	Our NGS Test	Closest Alternative (Standard Panel)
Precision	99.9% analytical sensitivity & specificity	~95% due to lower coverage
Methodology	NGS (Next‑Generation Sequencing) with full PLN gene coverage	Limited Sanger sequencing or targeted hot‑spot analysis
Turnaround Time	3 to 4 Weeks	6–8 Weeks
Regulatory Alignment	2026 DHA/MOHAP Standards, ISO 9001:2015	Variable

Physician Insight & Safety Protocol

“I understand the uncertainty that genetic heart conditions can bring. This test is a powerful tool for uncovering familial risk, but results must always be interpreted alongside a full clinical evaluation. Please never change your cardiac medications without first speaking to your cardiologist.”

— Dr. PRABHAKAR REDDY, DHA License No. 61713011

⚠️ Safety & Exclusion Criteria

This test is not for acute cardiac emergencies. If you experience sudden chest pain, severe shortness of breath, or fainting, seek emergency medical help immediately.
Do not discontinue any prescribed heart medications prior to testing unless directed by your doctor.
Testing requires prior genetic counselling; results may have psychological impact on relatives.
Sample must be collected by a trained phlebotomist; home collection is available only within 8 AM – 11 PM.

Medication Warning: Do not discontinue prescribed medication without consulting your doctor.

Patient FAQ & Clinical Guidance

1. What is the PLN gene test used for?

The PLN gene test identifies mutations in the phospholamban gene that cause hypertrophic cardiomyopathy type 18, enabling definitive diagnosis and family risk assessment.

يستخدم تحليل جين PLN لتحديد الطفرات المسببة لاعتلال عضلة القلب الضخامي من النوع 18، مما يتيح تشخيصًا نهائيًا وتقييمًا للمخاطر العائلية.

2. How is the sample collected and what is the process?

A blood sample, extracted DNA, or one drop of blood on an FTA card is collected by a trained phlebotomist during a premium home visit.

يتم جمع عينة دم أو حمض نووي مستخلص أو قطرة دم على بطاقة FTA بواسطة أخصائي سحب دم خلال زيارة منزلية متميزة.

3. How long do the results take and what do they mean?

Results are available within 3 to 4 weeks and are interpreted by your cardiologist to guide treatment, lifestyle adjustments, and family screening.

تتوفر النتائج خلال 3 إلى 4 أسابيع ويفسرها طبيب القلب لتوجيه العلاج وتعديل نمط الحياة وفحص أفراد الأسرة.

Accreditation: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). This adheres to Federal Decree-Law No. 41 of 2024 (Art. 87), UAE CDS Law 2026 (Minors), and UAE PDPL data privacy regulations. All genetic counselling and sample handling comply with DHA/MOHAP standards.

*Price shown is indicative and subject to insurance approval. Contact +971 54 548 8731 for verification.

دعم ثنائي اللغة متاح